Table 2. Overall analysis during the first and second periods, March 24 to December 31, 2019 and March 24 to December 31, 2020.
| Findings | 1 st period | 2 nd period | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| 2019 | 2020 | p value | 2019 | 2020 | p value | |
| Patients submitted to mammography | 5,661 | 927 | 10,155 | 9,394 | ||
| Age* | 52.1±11.24 | 50.4±10.27 | <0.001 | 51.5±11.04 | 51.7±10.76 | 0.218 |
| BI-RADS® 4 and 5† | 2.7 | 6.2 | <0.001 | 3.2 | 3.9 | 0.014 |
| Breast cancer | 36 | 18 | 98 | 110 | ||
| Breast cancer/1,000 patients‡ | 6.4 | 19.4 | <0.001 | 9.7 | 11.7 | 0.165 |
| Symptomatic or elevated risk§ | 55.6 | 88.9 | 0.016 | 61.2 | 60.0 | 0.857 |
| Aggressive subtypes¶ | 19.4 | 27.8 | 0.5 | 14.3 | 8.2 | 0.2 |
Results expressed as n, mean age±standard deviation or %.
* Mean age of patients submitted to mammography (standard deviation); † BI-RADS® 4 and 5 among BI-RADS® 1, 2, 3 and 4; ‡ rate of breast cancer/patients submitted to mammography; § percentage of breast cancer in patients presenting symptoms or elevated risk; ¶ percentage of more aggressive molecular subtypes (Her-2 and triple-negative).